

Resin selection to optimize the flexural strength of bioprocess film

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.

Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners.

© 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit $\underline{\text{cytiva.com/contact}}$





Resin selection to optimize the flexural strength of bioprocess film

GE Healthcare Authors – Susan Burke, PhD; Ross Acucena, BEng, MBA GE Global Research Authors – Andrew Burns, PhD; Greg Goddard, PhD Sealed Air Corporation Authors – Tiffani Burt, PhD; Jennifer Foreman, BS, MBA; Nicholas Berendt, MA

Abstract

Single-use bioprocess technology offers several advantages for manufacturing biopharmaceuticals, such as increased transportability of fluids throughout the bioprocess workflow and a greater diversity of systems to support specific unit operations (e.g., rocking bioreactors). However, due to the flexible nature of the plastic materials used to construct the single-use containers, the flexural properties of the bioprocess film are critical for performance in such applications. This poster focuses on how the resin selection and architecture of a bioprocess film can be optimized to maintain critical performance attributes, such as container integrity and gas barrier properties, under the significant forces during bulk liquid transportation and WAVE Bioreactor™ system applications.

Materials and methods


Material: Fortem™ film post-gamma irradiation (40-55 kGy). Control films are bioprocess films currently on the market.

Bis(2,4-di-tert-butylphenyl) phosphate (bDtBPP) analysis:

Extractions in water at temperature = 50°C, surface area to volume ratio: 0.37 cm²/mL, analysis with liquid chromatography-mass spectroscopy, limit of detection (LOD) and limit of qualification (LOQ): 2 ppb and 5 ppb, respectively.

Cell growth analysis: Test article: 2L containers made from Fortem film containing 200 mL of media (8 cm² of film/mL), control: media stored in glass containers. Control stored at 4°C for 7 days. Test containers rocked (6°, 20 rpm) for 3 days at 37°C and 4 days at room temperature (test and control protected from light). Three day cell culture with mAb-producting CHO DG44 cells in shaker flasks (initial viable cell density = 0.3×10^6 cells/mL). The CHO DG44 cell line is sensitive to bDtBPP down to 0.1 mg/L (100 ppb).

Growth performance [%] = $\left(\frac{PD_{bag}}{PD_{ref}}\right) \times 100$



Co-extruded film manufactured in Class 8 cleanroom. Supplied as double ply; contact layer only exposed to Class 5 air (Sealed Air Corp. film design patent).

Intoduction

Single-use bioprocess technology is becoming more mainsteam in the biopharmaceutical industry. However, there are a number of challenges that still remain, and system requirements continue to evolve. Over the past several years, materials of construction has been an area of focus due to observations of negative impact of extractable compounds from bioprocess film on the growth of certain sensitive cell lines (1, 2). As a result, the industry is now advancing toward developing single-use films that are better suited to fit the needs of biomanufacturing. Specifically, end users have communicated a need for improved film performance, a breadth of knowledge of material properties, with reliability of the supply. In order to achieve optimal performance of a film for bioprocess applications, it is important to map all of the required material performance attributes in applications across the entire bioprocess workflow. Designing a film with the right balance of attributes is key to achieving the desired performance.

Materials selections

Fluid contact layer – polyethylene and cyclic olefin copolymer (COC)

COC is compliant with EP 3.1.3, EP 3.1.5, JP 7.02, USP Class VI
COC acts as macromolecular slip agent, eliminating need for traditional small molecule additives

Gas barrier – two different types of EVOH (alcohol substitution) incorporated into structure

• Provides barrier to gases in both wet and dry conditions

Outer layer nylon and interior polyethylene blend


- Specific nylon chosen for outer layer to provide strength even in humid conditions
- Interior layers composed of polyethylene blend for robustness and flexibility over wide temperature range

Antioxidant package – selection of additives and placement in film optimized for minimal impact on mammalian cell culture performance

Connecting materials to architecture

Robustness vs flexibility: a challenge for rocking bioreactors and fluid transportation

Rocking motion and wave impact forces create unique forces on film.



Translation of film design to performance

Improved extraction profile

Concentration of bDtBPP found in extract (ppb)

 Sample
 Day 3
 Day 7

 Control (glass bottle)
 below LOD
 below LOD

 Control film 1
 6000-6500
 6000-6500

 Control film 2
 800-1000
 800-1000

 Control film 3
 25-35
 25-35

Cell culture performance – Fortem

Fortem

Population doubling (%)	Cell viability (%)
98 ± 3	94 ± 1

below LOD

Summary

To keep pace with the needs of the biomanufacturing industry, the films used in single-use bioprocess technology should be purposefully designed for bioprocess applications. With the new Fortem film, the combination of resin selection and film architecture has been carefully selected and skillfully optimized to deliver innovation.

- Achieves critical to quality attributes across applications selected data shown here.
 Mosts industry poods (o.g. sytractables data supply chain transparency)
- Meets industry needs (e.g., extractables data, supply chain transparency).
 Serves as a cornerstone technology for future advances in biomanufacturing applications.

References

To keep pace with the needs of the biomanufacturing industry, the films used in single-use bioprocess technology should be purposefully designed for bioprocess applications. With the new Fortem film, the combination of resin selection and film architecture has been carefully selected and skillfully optimized to deliver innovation.

- 1. Steiger, N and Eibl, R. Chemie Ingenieur Technik **85**, 26–28 (2013).
- 2. Hammond M. et al. PDA Journal of Pharma. Sci. and Technol. **67**, 123–134 (2013).

gelifesciences.com

GE, the GE Monogram, and WAVE Bioreactor are trademarks of General Electric Company.

Fortem is a trademark of Sealed Air Corporation. All other third party trademarks are the property of their respective owner.

© 2017 General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GF Healthcare which supplies

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them.

A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

GE Healthcare Bio-Sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden. For local office contact information, visit gelifesciences.com/contact.

29256263 AA 03/2017

below LOD